Evaluation of the AdvanDx VRE EVIGENE assay for detection of vanA in vancomycin-resistant Staphylococcus aureus

G E Fosheim; R B Carey; B M Limbago

doi:10.1128/JCM.02556-06

Evaluation of the AdvanDx VRE EVIGENE assay for detection of vanA in vancomycin-resistant Staphylococcus aureus

J Clin Microbiol. 2007 May;45(5):1611-3. doi: 10.1128/JCM.02556-06. Epub 2007 Mar 7.

Authors

G E Fosheim¹, R B Carey, B M Limbago

Affiliation

¹ Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, Centers for Disease Control and Prevention, MS C16, 1600 Clifton Rd., Atlanta, GA 30333, USA.

Abstract

AdvanDx VRE EVIGENE, a commercial vanA/vanB DNA hybridization assay to identify vancomycin-resistant enterococci (VRE), was evaluated for the detection of vanA in Staphylococcus aureus. Performance was assessed using S. aureus, VRE, and vancomycin-intermediate and -susceptible isolates. The assay demonstrated 100% sensitivity and specificity when analyzed visually and by optical density.

Publication types

Evaluation Study

MeSH terms

Bacterial Proteins / analysis*
Bacterial Proteins / genetics*
Carbon-Oxygen Ligases / analysis*
Carbon-Oxygen Ligases / genetics*
DNA, Bacterial
Microbial Sensitivity Tests
Nucleic Acid Hybridization / methods*
Sensitivity and Specificity
Staphylococcus aureus / drug effects*
Staphylococcus aureus / genetics*
Vancomycin Resistance*

Substances

Bacterial Proteins
DNA, Bacterial
VanA ligase, Bacteria
Carbon-Oxygen Ligases